D.E. Shaw & Co
VIRX

D.E. Shaw & Co’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

D.E. Shaw & Co’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-26,883
Closed -$98K – 6029
2021
Q4 		$98K Sell
26,883
-9,379
-26% -$50K ﹤0.01% 5066
2021
Q3 		$291K Buy
+36,262
New +$357K ﹤0.01% 4366
2017
Q2 		– Sell
-854
Closed -$123K – 3580
2017
Q1 		$123K Buy
854
+163
+24% +$23.3K ﹤0.01% 3180
2016
Q4 		$87K Buy
691
+223
+48% +$31K ﹤0.01% 3355
2016
Q3 		$72K Sell
468
-631
-57% -$89.1K ﹤0.01% 3310
2016
Q2 		$126K Sell
1,099
-20
-2% -$2.22K ﹤0.01% 3232
2016
Q1 		$126K Sell
1,119
-7
-0.6% -$1.06K ﹤0.01% 3259
2015
Q4 		$212K Buy
1,126
+732
+186% +$137K ﹤0.01% 3536
2015
Q3 		$67K Sell
394
-2,107
-84% -$760K ﹤0.01% 3644
2015
Q2 		$1.58M Sell
2,501
-43
-2% -$22.9K ﹤0.01% 2382
2015
Q1 		$1.31M Sell
2,544
-1,098
-30% -$554K ﹤0.01% 2344
2014
Q4 		$1.95M Buy
3,642
+3,579
+5,681% +$1.61M ﹤0.01% 2305
2014
Q3 		$94K Sell
63
-1,005
-94% -$1.45M ﹤0.01% 3990
2014
Q2 		$1.46M Sell
1,068
-257
-19% -$298K ﹤0.01% 2584
2014
Q1 		$1.84M Sell
1,325
-1,341
-50% -$1.56M ﹤0.01% 2473
2013
Q4 		$2.65M Buy
2,666
+1,267
+91% +$1.31M ﹤0.01% 2248
2013
Q3 		$1.46M Buy
1,399
+1,096
+362% +$1.17M ﹤0.01% 2705
2013
Q2 		$332K Buy
+303
New +$338K ﹤0.01% 3512

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co's VIRX Position: Q1 2022 in Review

D.E. Shaw & Co sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2022, closing a stake of 26,883 shares — an estimated $98K sold.

D.E. Shaw & Co first reported a position in VIRX in Q2 2013 and held it in 18 quarters. The position peaked at $2.65M in Q4 2013. 69 funds tracked by Wall St. Rank hold VIRX as of Q1 2022.

  • D.E. Shaw & Co reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 26,883 Viracta Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $98K.
  • D.E. Shaw & Co first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
  • D.E. Shaw & Co's Viracta Therapeutics, Inc. Common Stock position peaked at $2.65M in Q4 2013.
  • 69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.